News & Videos - VIVESTO AB [CBOE]

Oasmia Pharmaceutical is a specialty pharmaceutical company focused on developing new therapeutic options for patients ......

Sareum Holdings is a UK-based drug development company, specialising in small molecule kinase inhibitors. • Tell us about your ......

Edison Investment Research Limited Oasmia Pharmaceutical (OASM): Focused on pillars of growth 08-Oct-2021 / 10:18 GMT/BST London, UK, 8 October 2021 Oasmia Pharmaceutical (OASM): Focused on pillars of growth Oasmia Pharmaceutical has made steady progress in its ongoing transition into an R&D-driven, speciality pharma company with commercially available assets. The in-licensing of Cantrixil from Kazia Therapeutics in March is the first of its 'string of pearls' strategy to bolster the pipeline....

Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs that are delivered intravenously through ......

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM) 09-Sep-2020 / 14:59 GMT/BST London, UK, 9 September 2020 Edison issues initiation on Oasmia Pharmaceutical (OASM) Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs through its proprietary XR-17 platform technology. Its technology has received validation though a global partnership deal for lead asset...

The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the preferential rights issue completed in December 2019. As a result of the preferential rights issue, the number of shares and votes has increased by 199,275,352 from 249,094,194 to 448,369,546. The share capital has increased by SEK 19,927,535.20 from SEK 24,909,419.40 to SEK 44,836,954.60. For more information: Urban Ekelund, Investor Relations Oasmia E-mail: [email protected] Phone: +46 18-50 54 40...

EVENTS IN SECOND QUARTER Oasmia ADSs were delisted from NASDAQ in the US to reduce complexity and costs. Oasmia recruited two General Managers to its management team. Oasmia published its annual report for 2018/2019 and adjusted accounts due to write-downs. The company’s auditors did not recommend former Board to be granted discharge from liability. The special examiner appointed by Oasmia’s Board, Svante Forsberg (Deloitte), submitted his report on investigation of liability issues ahead of...

Oasmia Pharmaceutical AB ("Oasmia" or "the Company") CEO Sven Rohmann and the Chairman of the Board Jörgen Olsson today announced that they have purchased 978,944 and 900,000 subscription rights respectively. Both Sven Rohmann and Jörgen Olsson have announced that they intend to exercise the subscription rights to subscribe for new shares in Oasmia in the Company's ongoing rights issue. For more information: Urban Ekelund, IR Manager Oasmia E-mail: [email protected] About Oasmia Pharmaceutical AB...

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). See the section “IMPORTANT INFORMATION” below. The board of Oasmia Pharmaceutical AB...

Michael af Winklerfelt has been appointed as new CFO of Oasmia Pharmaceutical AB. He will be a member of the management team and will take up his position on November 4. Michael af Winklerfelt is 47 years old and was most recently with a British venture capital company, where in recent years he has worked with financial control as well as business and strategy development in a medtech company in the US. He has wide-ranging international experience in the role of CFO from a number of industries...

EVENTS IN FIRST QUARTER Oasmia presented results from two clinical studies of Docecal in patients with metastatic breast cancer The Board of Directors appointed a special examiner to give all shareholders basis for decision regarding discharge from liability before the AGM Oasmia has found questionable transactions between Oasmia and companies controlled by former chairman Julian Aleksov that have not been reported. The Board of Directors decided to report these transactions to the Swedish...

Oasmia will hold an audiocast and telephone conference on Thursday 26 September at 10:00 (CET) to present the company's Q1 report for the financial year 2019/2020. The presentation of the Q1 report will be in English. Presenters will be Jörgen Olsson, Chairman of the Board, and Sven Rohmann, interim CEO. The audiocast is viewed via the link https://tv.streamfabriken.com/oasmia-pharmaceutical-q1-2019-2020 It will be possible to ask texted questions directly via the Audiocast solution. Telephone...

Oasmia has further strengthen its management team with the recruitment of two General Managers to accelerate commercialization of Oasmia. Neil Yman is appointed General Manager for Europe & Russia and Reinhard Koenig is appointed General Manager for USA & Canada. Both have extensive experience of leading positions within global pharmaceutical companies. “The addition of two experienced General Managers will drive the commercial success in their territory respectively. Oasmia has now a...

New York, New York--(Newsfile Corp. - September 4, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia") or the "Company") of the September 27, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Oasmia stock or options between October 23, 2015 and July 9, 2019 and would like to discuss your legal rights, click here...

During the preceding weekend, the initially yearly promissory note loan which Nexttobe provided to Oasmia back in 2015 has finally fallen due after several extensions. Also, it was the intended refinancing of this loan that gave rise to Oasmia’s issuance to Arwidsro and MGC of warrants for subscription, which warrants in turn gave rise to the so called ownership dispute, after MGC having acquired this loan claim in August 2018 mainly against deferred payment. In the relation between Arwidsro...

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced today that it intends to delist its American Depositary Shares (“ADS”) from the Nasdaq Capital Market (“NASDAQ”) and to deregister and terminate its reporting obligations with the Securities and Exchange Commission (“SEC”). Oasmia expects the delisting to become effective on or about August 22, 2019. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Oasmia...

Oasmia will hold an audiocast and telephone conference on Friday 28 June at 09:00 (CET) to present the company's full-year report for the financial year 2018/2019 and the status of the board's previously communicated review of the company. The presentation of the full-year report and the status of the board's review will be in English. The audiocast is viewed via the link https://tv.streamfabriken.com/oasmia-year-end-report . It will be possible to ask textual questions directly via the...

Two weeks ago, March 19 th , the Extra General Meeting in Oasmia elected a new Board on the initiative of the main owner Arwidsro. The new Board has since then taken control over the Company and started implementing new governance and initiated due diligence of the most important matters determining the value of the Company. (Italicized below from press release, March 21). A review of product and distribution strategy to ensure that Oasmia will succeed as planned. To increase possibilities to...

The study (OAS-04-01) was a tolerance and pharmacokinetic study where the dose for Apealea (paclitaxel micellar) was determined. This phase I study was conducted at two clinics in Sweden located in Lund and Umeå between 2004 and 2007. The 34 patients included in the study had different forms of refractory cancers with solid tumours. The detailed pharmacokinetic results together with the tolerance assessments have been summarized in a manuscript that is now being published in the peer-review...

Notification from Oasmia Pharmaceutical AB Uppsala, Sweden, March 26, 2019 – The Swedish Securities Council has today published a statement regarding Oasmia. For statement please click here (only in Swedish). About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery...